A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HIV-1 VACCINE TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF LOW DOSE MN RSGP120/HIV-1 (GENENTECH) IN COMBINATION WITH QS21 ADJUVANT OR ALUM IN HEALTHY ADULTS: